Conserved HBV and HCV sequences useful for gene silencing

Details for Australian Patent Application No. 2005319306 (hide)

Owner Alnylam Pharmaceuticals, Inc.

Inventors Pachuk, Catherine; Zurawski, Vincent Jr.; Satishchandran, Chandrasekhar; Mintz, Liat

Agent Allens Arthur Robinson

Pub. Number AU-B-2005319306

PCT Pub. Number WO2006/069064

Priority 60/638,294 22.12.04 US

Filing date 20 December 2005

Wipo publication date 29 June 2006

Acceptance publication date 12 January 2012

International Classifications

A61K 31/713 (2006.01) - Double-stranded nucleic acids or oligonucleotides

C12N 15/113 (2010.01) Mutation or genetic engineering - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides

Event Publications

19 July 2007 PCT application entered the National Phase

  PCT publication WO2006/069064 Priority application(s): WO2006/069064

7 May 2009 Assignment before Grant

  Nucleonics, Inc. The application has been assigned to Alnylam Pharmaceuticals, Inc.

12 January 2012 Application Accepted

  Published as AU-B-2005319306

10 May 2012 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2005319313-Methods, systems and computer program products for connecting and monitoring network equipment in a telecommunications system

2005319305-Pyrrolidine inhibitors of IAP